Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 73Cr 65Cr 60Cr 54Cr 102.67Cr 6.81TCr 105.22Cr 714.08Cr 284.62Cr 3.65TCr 272.79Cr 266.95Cr 11TCr P/E 2026 *
3.59x
P/E 2027 * 3.33x
Enterprise Value 73Cr 65Cr 60Cr 54Cr 102.67Cr 6.81TCr 105.22Cr 714.08Cr 284.62Cr 3.65TCr 272.79Cr 266.95Cr 11TCr EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.47x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+6.49%
1 week+36.85%
Current month+35.29%
1 month+23.95%
3 months+16.91%
6 months+13.55%
Current year+40.50%
1 week 3.4
Extreme 3.4
4.76
1 month 3.38
Extreme 3.38
4.76
Current year 2.95
Extreme 2.95
5.78
1 year 2.31
Extreme 2.31
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Free

Director

3,694 0.0022%
20/07/26 Free

Chief Technology Officer

1,37,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-1,27,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
+6.49%+36.85%+87.15%-50.26% 73Cr
+4.40%-0.11%+45.80%+138.35% 1,20600Cr
+2.25%+4.38%+49.89%+91.57% 66TCr
+0.79%+1.72%+34.33%+112.84% 51TCr
+2.77%+0.98%+43.81%+68.46% 38TCr
+1.35%+0.12%+71.22%+45.08% 36TCr
+0.29%+1.48%+30.59%+58.32% 31TCr
+0.98%+1.49%+7.16%+34.78% 29TCr
+0.82%-0.17%+43.57%+75.97% 25TCr
+1.47%-0.56%+43.36%+125.90% 21TCr
Average +2.06%+1.16%+45.69%+70.10% 41.8TCr
Weighted average by Cap. +2.24%-1.95%+43.03%+95.94%

Financials

2026 *2027 *
Net sales 47Cr 42Cr 39Cr 35Cr 67Cr 4.42TCr 68Cr 463.21Cr 184.62Cr 2.37TCr 176.95Cr 173.16Cr 7.45TCr 49Cr 44Cr 41Cr 37Cr 70Cr 4.63TCr 72Cr 485.43Cr 193.48Cr 2.48TCr 185.44Cr 181.47Cr 7.81TCr
Net income 20Cr 18Cr 17Cr 15Cr 29Cr 1.91TCr 29Cr 199.72Cr 80Cr 1.02TCr 76Cr 75Cr 3.21TCr 22Cr 20Cr 18Cr 16Cr 31Cr 2.06TCr 32Cr 216.03Cr 86Cr 1.1TCr 83Cr 81Cr 3.48TCr
Net Debt - -
Projected Income Statement - Annual - Ironwood Pharmaceuticals, Inc.
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
10/26/10 $4.735 +7.86% 31,37,261
06/26/06 $4.390 +8.93% 39,63,432
05/26/05 $4.030 +6.90% 49,89,223
04/26/04 $3.770 +7.71% 25,71,635
03/26/03 $3.500 +1.16% 19,47,080
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.390USD
Average target price
6.100USD
Spread / Average Target
+38.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ironwood Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IRWD Stock